Get startedLog in
    Picture of Enveric Biosciences logo

    ENVB — Enveric Biosciences News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapSucker Stock
    All News

    Enveric Biosciences Q3 net loss widens

    Picture of Enveric Biosciences logoEnveric Biosciences
    14/11/2025 21:18
    Overview

Enveric Q3 net loss at $3.4 mln, EPS at -$10.81

Completed reverse stock split to address Nasdaq bid price deficiency

Outlook

Enveric plans to submit IND application for EB-003 in 2026

Company aims for first-in-human trial of EB-003 in 2026

Result Drivers

HEADQUARTERS RELOCATION - Relocated to Cambridge, MA to leverage the biotech hub for advancing EB-003

Key Details


    MetricBeat/MissActualConsensus Estimate
    Q3 EPS-$10.81
    Q3 Net Income-$3.4 mln
    

Analyst Coverage

Wall Street's median 12-month price target for Enveric Biosciences Inc is $120.00, about 95.5% above its November 13 closing price of $5.46

Press Release: ID:nBw4kR0rNa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

    Recent news on Enveric Biosciences

    See all news